GlassScriptPhysician profile
Sonali P Birewar
NPI 1043310352
$3,357.77
in general payments reported to CMS, 2019-2025
25 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $259 · 2021: $357 · 2022: $746 · 2023: $841 · 2024: $345 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $554.00 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $347.33 | 2019-2024 | Veltassa |
| Amgen INC. | $341.49 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $250.33 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $245.42 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $232.60 | 2019-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $194.85 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $141.57 | 2019-2024 | Rayaldee |
| Ani Pharmaceuticals, INC. | $137.57 | 2022-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $130.64 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $118.97 | 2019-2023 | Ultomiris |
| Medtronic, INC. | $89.89 | 2023 | Ellipsys Vascular Access System, Vanta Adaptivestim |
| Mallinckrodt Hospital Products INC. | $87.11 | 2020-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $84.71 | 2024 | |
| Akebia Therapeutics INC | $78.20 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $66.04 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $57.88 | 2019 | |
| Calliditas Therapeutics US INC. | $39.15 | 2022 | |
| Amag Pharmaceuticals, INC. | $31.83 | 2019-2020 | |
| Daiichi Sankyo INC. | $27.71 | 2025 | Injectafer |
| Ardelyx, INC. | $22.90 | 2024 | Ibsrela |
| Veloxis Pharmaceuticals, INC. | $22.74 | 2020 | |
| Itamar Medical INC | $20.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.19 | 2024 | Jardiance |
| Nxstage Medical, INC. | $15.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonali Birewar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.